Previous studies have reported the potential therapeutic effects of MEG3 in AD, as overexpression of MEG3 was shown to improve cognitive disorders, reduce nerve damage, and inhibit astrocyte activation in the hippocampal tissues by inhibiting the PI3K/Akt signaling pathway in rats (Yi et al., 2019). The gene discussed is MEG3; the disease is cognitive disorder.